Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 5;12:720571. doi: 10.3389/fimmu.2021.720571

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Deng, Liu, Yuan, Zhang, Cui, Li, Yuan, Wang, Wang and Deng

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Clinical responses of the humanized anti-BCMA CAR-T cell therapy. (A) Pt_with 1,2,5,6,7 (5/7, 71.4%) and Pt_without 4,6,8 (3/13, 23.1%) developed disease progression again and died of their primary disease. (B) There was no difference in ORR between patients with and without extramedullary disease when they achieved the best effect (P=0.876). (C) M protein levels increased again in Pt_with 5,7 when their disease progressed again, but it did not increase when the disease of Pt_with 1,2,6 progressed again. (D) All the patients with disease progression were accompanied by an increase of M protein level.